About United Therapeutics Corporation

United Therapeutics Corporation, founded in 1996, has become the world's leading company in pulmonary arterial hypertension (PAH) treatments, developing and commercializing multiple innovative therapies that have transformed patient outcomes. The company has built a comprehensive platform in rare lung diseases. UTHR stock price reflects the company's market leadership and continued innovation in addressing severe rare diseases.

Led by CEO Martine Rothblatt, who founded the company, United Therapeutics has consistently advanced scientific innovation while building a sustainable commercial franchise in rare diseases. The management team has demonstrated exceptional ability to develop complex therapies and navigate regulatory pathways for rare disease treatments. Leadership's vision for developing life-saving therapies for patients with limited options has been instrumental in creating significant value and driving UTHR stock price appreciation.

United Therapeutics operates by developing and commercializing innovative therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other rare conditions affecting lung function. The company generates substantial revenue from approved products while continuing to invest in pipeline development. With established commercial products providing strong cash generation, multiple pipeline programs offering continued growth potential, and leadership in rare lung diseases where successful treatments command premium pricing, UTHR offers investors exposure to innovative rare disease therapeutics with both current profitability and significant pipeline value in addressing conditions with few treatment alternatives.